Trials / Completed
CompletedNCT01639014
Effect of F2695 on Functional Recovery After Ischemic Stroke
Effect of 3-month Treatment With F2695 (75mg OD) on Improving Functional Recovery of Patients With Ischemic Stroke. A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-Controlled Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 532 (actual)
- Sponsor
- Pierre Fabre Medicament · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the efficacy of a new serotonin-norepinephrine reuptake inhibitor (SNRI) nin functional recovery after ischemic stroke.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | F2695 | 75 mg OD in 2 capsules |
| DRUG | placebo | 2 capsules |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2015-02-01
- Completion
- 2015-02-01
- First posted
- 2012-07-12
- Last updated
- 2015-04-01
Locations
87 sites across 11 countries: Belgium, Czechia, France, Germany, Hungary, Italy, Portugal, Russia, Spain, Sweden, Switzerland
Source: ClinicalTrials.gov record NCT01639014. Inclusion in this directory is not an endorsement.